WHWK
NASDAQ · Biotechnology
Whitehawk Therapeutics Inc
$2.76
+0.05 (+1.85%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.02M | 8.91M | 7.24M |
| Net Income | 2.49M | 2.41M | 1.66M |
| EPS | — | — | — |
| Profit Margin | 27.6% | 27.1% | 22.9% |
| Rev Growth | -0.9% | +22.0% | +4.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 44.41M | 47.83M | 54.68M |
| Total Equity | 87.59M | 88.94M | 80.81M |
| D/E Ratio | 0.51 | 0.54 | 0.68 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 4.05M | 4.31M | 3.06M |
| Free Cash Flow | 1.13M | 1.46M | 1.28M |